The New Zealand Brain Tumor Trust

We are fundraising for the USPIO clinical trial that appears both diagnostic and therapeutic.

Limited clinical trial opportunities exist for brain tumour patients in New Zealand and around the world. The NZBTT wants to change this.

A pilot clinical trial (the USPIO study-Ethics reference 17/CEN/176) based at Dunedin Hospital has investigated if an MRI brain scan coupled with a known medication can better image brain tumours before surgery.  Preliminary results are very successful and that this opens a new world of diagnostic information. This helps to improve diagnostic imaging and later complete removal of brain tumours. 

The pilot study showed that some tumours had additional regions of enhancement and patient survival may also be promoted.

The pivotal study will be led by Neurosurgeon Mr Ahmad Taha along with Christchurch Hospital Clinicians, and Research led by Associate Professor Tania Slatter at the Otago Medical School, University of Otago. 

The pivotal trial will now take more participants to further delineate the diagnostic advantages and confirm the survival effect.

In this graph we show four groups of patients divided according to the type of tumour (two tumour types) and whether or not they participated in the USPIO study.

Group A– The green dots are many patients (with one type of tumour) and time of their death after diagnosis showing (on the horizontal line) less than 20 months survival. This group did not participate in the USPIO study.

Group B– The black squares are many patients (with another type of tumour) and time of their death after diagnosis showing (on the horizontal line) with up to 100 months survival. This seems to be a better type tumour to have (compared to green dots). This group did not participate in the USPIO study.

Group B USPIO– The red squares are a few patients (with the black square-type tumour) with time of their death after diagnosis showing (on the horizontal line) up to 100 months survival. This group participated in the USPIO trial.

Group A USPIO- The blue dots are a few patients (with the green dot-type tumour) with survival time after diagnosis. Everyone lived for at least 20 months (showing on the horizontal line) and some are still going. This group participated in the USPIO trial. Survival (from the green to blue line) has advanced considerably for this group (compare green dot line and blue dot line).

This clinical trial is open to those with glioblastoma or brain metastasis from cancers elsewhere in the body. Please contact Neurosurgeon Mr Ahmad Taha at Dunedin Hospital or Dr Noelyn Hung  for further information (NZBTTemail@gmail.com).

Have a brain tumour trial to bring to NZ? Please contact us.

Skip to content